CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞淋巴增殖性疾病干细胞移植后的 CAR-T：它们真的是自体还是异体细胞疗法？
英文原题：CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
查看英文原题
CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
异基因造血干细胞移植（allo-HSCT）是B细胞淋巴增殖性疾病的标准治疗方法之一；然而，allo-HSCT后深度复发很常见，且与不良预后相关。克服这些复发的一种成功方法是利用嵌合抗原受体（CAR）T细胞调动人体自身免疫系统。这两种方法有可能联合用于治疗R/R B细胞淋巴增殖性疾病。多项临床试验描述了allo-HSCT与CAR-T 序贯联合的不同场景。此外，对于所有移植患者，嵌合体评估对于评价植入成功与否很重要。然而，对于既往接受过allo-HSCT的患者，在制备CAR-T 细胞之前没有进行嵌合体监测。在本综述中，我们聚焦于allo-HSCT和CAR-T 治疗以及用于制备CAR-T 细胞的不同T细胞来源。
展开英文摘要原文
Allogenic hematopoietic stem cell transplantation (allo-HSCT) is one of the standard treatments for B-cell lymphoproliferative disorders; however, deep relapses are common after an allo-HSCT, and it is associated with poor prognosis.
A successful approach to overcome these relapses is to exploit the body's own immune system with chimeric antigen receptor (CAR) T-cells. These two approaches are potentially combinatorial for treating R/R B-cell lymphoproliferative disorders. Several clinical trials have described different scenarios in which allo-HSCT and CAR-T are successively combined.
Further, for all transplanted patients, assessment of chimerism is important to evaluate the engraftment success. Nonetheless, for those patients who previously received an allo-HSCT there is no monitorization of chimerism before manufacturing CAR T-cells. In this review, we focus on allo-HSCT and CAR-T treatments and the different sources of T-cells for manufacturing CAR T-cells.
论文信息
- 作者
- Bartoló-Ibars A、Uribe-Herranz M、Muñoz-Sánchez G、Arnaldos-Pérez C、Ortiz-Maldonado V、Urbano-Ispizua Á、Pascal M、Juan M
- 单位
- Immunology Service-CDB, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.Spain
- 文献类型
- 综述
- 期刊
- Cancers2021 Sep 17
- 原文标识
- PubMed 34572890 · DOI 10.3390/cancers13184664
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →